Abstract:
:Tiagabine (TGB), a recently approved antiepileptic drug (AED), has a specific mechanism of action that is unique among AEDs. A potent AED with linear, predictable pharmacokineties, it inhibits gamma-aminobutyric acid (GABA) reuptake into neurons and glia. Tiagabine does not have any clinically relevant effects on hepatic metabolism or on serum concentrations of other AEDs, nor does it interact with commonly used non-AEDs. The most common side effects of TGB in controlled studies are dizziness, asthenia, somnolence, accidental injury, infection, headache, nausea, and nervousness. These events are usually mild to moderate in severity and generally do not require medical intervention. At dosages of 30-56 mg daily, TGB is an effective add-on treatment for partial seizures. Although patients who have medically refractory epilepsy can be converted to TGB monotherapy, more controlled studies are necessary to confirm the efficacy of TGB as monotherapy and to determine the effective dosage range.
journal_name
Clin Neuropharmacoljournal_title
Clinical neuropharmacologyauthors
Schachter SCkeywords:
subject
Has Abstractpub_date
1999-11-01 00:00:00pages
312-7issue
6eissn
0362-5664issn
1537-162Xjournal_volume
22pub_type
杂志文章,评审abstract::Several recent reports attest to zolpidem's strong potential for abuse, dependence, and severe withdrawal symptoms upon its discontinuation. We report, for the first time, on 1 case of heavy zolpidem abuse and dependence with severe withdrawal symptoms twice treated safely and successfully with pregabalin, a newer ant...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0b013e31820a3b5a
更新日期:2011-03-01 00:00:00
abstract::Acute psychotic episodes represent critical situations during the course of schizophrenia. Olanzapine (OLZ), a second-generation antipsychotic, is efficacious in acute settings at dosages of 5 to 20 mg/d, and it can be considered a first-line treatment for patients with an acute episode of schizophrenia. The aim of th...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/01.WNF.0000220819.71231.96
更新日期:2006-05-01 00:00:00
abstract:OBJECTIVE:To describe an unusual case of camptocormia responding to levodopa. METHODS:We present a case of camptocormia with a sustained excellent response to levodopa in a patient with negative dopamine transporter and no DYT 5 genetic mutations. RESULTS:We present a 52-year-old man with 2 years' history of progress...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000024
更新日期:2014-03-01 00:00:00
abstract::Cyclosporine A (CsA) neurotoxicity is an iatrogenic disease with significant morbidity and occasional mortality. We retrospectively reviewed the cases of CsA neurotoxicity among bone marrow transplant recipients at our institution, and summarized the current literature on the subject. The neurologic presentation is va...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/00002826-199903000-00001
更新日期:1999-03-01 00:00:00
abstract::Recent studies have suggested that deprenyl may exert a neuroprotective influence and thus retard progression of Parkinson's disease (PD). On the other hand, the data do not disprove that deprenyl is primarily another form of symptomatic therapy like levodopa. Longitudinal Gompertzian analysis demonstrates the absence...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:
更新日期:1991-12-01 00:00:00
abstract::Six males and one female with chronic tic disorders, whose ages ranged from 12 to 31 years, were evaluated before treatment, after 1 month on placebo, after a single 10 mg nifedipine dose (three patients), and monthly while on flunarizine 10-15 mg (mean dose of 13 mg). None of the patients receiving nifedipine improve...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-199002000-00008
更新日期:1990-02-01 00:00:00
abstract::The effect of bromocriptine at doses up to 20 mg/day was studied in a single-blind format with a placebo phase in 15 Parkinson's disease patients with mild-to-moderate disability who had not been previously treated with levodopa. For the 11 patients who completed the 9 month trial, both Northwestern University Disabil...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:
更新日期:1987-04-01 00:00:00
abstract::In rodents, serotonin (5-HT) antagonists counteract behavioral and biochemical effects of neuroleptic drugs. Therefore, we have studied the effect of different 5-HT drugs and one anticholinergic drug in acute dystonia in five cebus monkeys chronically treated with haloperidol. Acute dystonia induced by subcutaneous in...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-198602000-00010
更新日期:1986-01-01 00:00:00
abstract:OBJECTIVE:Neuroleptic malignant syndrome was induced by aripiprazole in a 12 1/2-year-old boy. The patient had a history of reactive airway disease, pervasive developmental disorder, and learning disability. METHOD:The patient was interviewed and examined, and additional history was taken from the medical records. The...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/01.WNF.0000240941.13876.5E
更新日期:2007-01-01 00:00:00
abstract::Prion diseases are invariably fatal. Recently, quinacrine and chlorpromazine have been suggested as immediate candidates for the treatment of Creutzfeldt-Jakob disease and other prion diseases. The objective of this paper was to report on 2 fatal familial insomnia patients whose overall condition worsened despite quin...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/01.wnf.0000134853.36429.0e
更新日期:2004-07-01 00:00:00
abstract:OBJECTIVE:We present 3 new cases of psychotic symptoms in patients with adult attention-deficit/hyperactivity disorder while regularly treated with a stimulant therapy with methylphenidate. METHODS:Existing literature about this theme is reviewed, and potential mechanisms are discussed. RESULTS AND CONCLUSIONS:Medica...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/WNF.0b013e3181e29174
更新日期:2010-07-01 00:00:00
abstract:OBJECTIVE:Multiple sclerosis (MS) is a degenerative neurological condition that results in impairments in multiple domains including cognition, fatigue, and mood. Dalfampridine-extended release (D-ER) has been approved to improve walking in persons with MS. It is plausible that D-ER could improve cognition, fatigue, an...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000130
更新日期:2016-03-01 00:00:00
abstract:BACKGROUND:Serotonin syndrome (SS) is a potentially life-threatening condition that can be caused by use of proserotonergic drugs. Several studies have reported that combined administration of various medications may induce SS. We report a case of SS in a patient who was being treated with dopaminergic and noradrenergi...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000220
更新日期:2017-07-01 00:00:00
abstract::Oxidant stress resulting from excess dopamine (DA) may contribute to the development and progression of Parkinson's disease (PD). Free radicals resulting from the enzymatic metabolism of DA are most often discussed in this regard. However, levodopa (L-DOPA) and DA can also undergo autooxidation, producing free radical...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199619040-00010
更新日期:1996-08-01 00:00:00
abstract::We studied the effect of inhibiting the enzyme catechol-O-methyltransferase (COMT) by a novel COMT inhibitor, entacapone, on the pharmacokinetics and metabolism of levodopa in 12 healthy male volunteers. Single increasing oral doses of entacapone (50-400 mg) were administered concomitantly with a single oral dose of l...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199304000-00007
更新日期:1993-04-01 00:00:00
abstract::A 56 year-old woman who suffered from parkinsonism, oro-lingual dyskinesia (OLD) and tardive akathisia (TA) due to sulpiride is reported. OLD and TA appeared after sulpiride withdrawal. The patient was successfully treated with tetrabenazine even a mild parkinsonism was present. TA seems to be related with an apparent...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199410000-00013
更新日期:1994-10-01 00:00:00
abstract::Fifty-six chronic schizophrenic patients were randomized into haloperidol decanoate (HD) or placebo groups for 48 weeks of double-blind treatment. The double-blind trial was preceded by a 15-week single-blind run-in period, during which all patients were treated with 60 mg of HD (approximately corresponding to 3.6 mg ...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:
更新日期:1991-01-01 00:00:00
abstract::The latency of P300 "cognitive" event-related potentials changes if cholinergic activities of the central nervous system are pharmacologically manipulated. We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00002826-200101000-00007
更新日期:2001-01-01 00:00:00
abstract::Botulinum toxin A (BTA) is considered an effective treatment of cervical dystonia. The aim of this prospective, randomized, double-blind study was to compare Botox and Prosigne, a BTA of Chinese origin, with a view to establish the safety, the efficacy, and the equivalence of doses of the 2 formulations in the treatme...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/WNF.0b013e3181c46f48
更新日期:2010-01-01 00:00:00
abstract::The capacity of peripheral blood mononuclear cells (PBMCs) of anorexia nervosa (AN) patients to produce interleukin-1 (IL-1), interleukin-2 (IL-2), and interleukin-3-like activity (IL-3-LA) was studied. A significantly lower (-49%, p < 0.005) capacity to synthesize IL-2 and an almost significantly impaired ability (-3...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199306000-00007
更新日期:1993-06-01 00:00:00
abstract::Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addit...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199508000-00009
更新日期:1995-08-01 00:00:00
abstract::Midazolam, a potent short-acting benzodiazepine, is a safe and highly effective agent for the control of status epilepticus. Its efficacy in the control of neonatal seizures, however, has not been determined. Six neonates (aged 1-9 days; gestation, 30-41 weeks) developed seizures from a variety of causes. In each case...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-199619020-00005
更新日期:1996-04-01 00:00:00
abstract::Sargramostim (GM-CSF) therapy was instituted in a 49-year-old woman with hepatitis C on chronic interferon alpha-2b therapy. Within two weeks, she developed progressive confusion, lethargy, and gait disturbance. At autopsy 4 months later, diffuse perivascular nonmonoclonal lymphoid infiltrates were demonstrated throug...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:
更新日期:1999-09-01 00:00:00
abstract:BACKGROUND AND PURPOSE:Treatment of chronic insomnia with nightly hypnotics is efficacious, but discontinuation is recommended after 1 month, less than the average disease duration. This study was undertaken to determine the efficacy of intermittent administration. PATIENTS AND METHODS:A double-blind study was carried...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/wnf.0b013e3180674e0e
更新日期:2008-01-01 00:00:00
abstract:OBJECTIVE:There has been an increase in the European and North American schizophrenia literature discussing the high prevalence of metabolic syndrome induced by atypical antipsychotic agents. The aim of this article was to review available data on metabolic syndrome induced by atypical antipsychotic agents in patients ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/WNF.0b013e31824d5288
更新日期:2012-05-01 00:00:00
abstract::Drugs (e.g., PCP) which interfere with glutamatergic transmission at the N-methyl D-aspartate (NMDA) subclass of glutamate receptors precipitate both positive and negative symptoms of psychosis in humans. Based on a proposed "glutamatergic deficiency" in schizophrenia, pharmacologic facilitation of NMDA-mediated neura...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199106000-00012
更新日期:1991-06-01 00:00:00
abstract:OBJECTIVE:The aim of this study was to report the case of a male patient with Parkinson disease who developed brachial plexopathy (BP) due to varicella-zoster virus, which was successfully treated with human immunoglobulin. METHOD:We report the case of a 75-year-old male subject with a diagnosis of Parkinson disease w...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000195
更新日期:2017-01-01 00:00:00
abstract::Transient global amnesia (TGA) has been proposed as a possible adverse effect of sildenafil. There are rare cases in the literature, but none had strong evidence to support. Our case is the first to demonstrate a focal punctate diffusion-weighted imaging lesion at the right hippocampus after the use of sildenafil. Thi...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000383
更新日期:2020-03-01 00:00:00
abstract::Newly introduced dopamine agonists, such as ropinirole, may offer advantages compared to such older drugs as bromocriptine in patients with advanced Parkinson's disease (PD) with response oscillations or waning efficacy. Dose equivalence of these two drugs, however, has not been well established, which may complicate ...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-200111000-00006
更新日期:2001-11-01 00:00:00
abstract::Male albino rats received a stereotaxic injection of 6-hydroxydopamine (6-OHDA) into the right substantia nigra. Animals demonstrating contralateral rotations 2 weeks postoperatively with apomorphine (0.5 mg/kg i.p.) were treated with L-Dopa (55 mg/kg i.p.), bromocriptine (2 mg/kg i.p.), or polyethylene glycol (vehicl...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:
更新日期:1984-01-01 00:00:00